A CASE OF CEREBRAL ABSCESS DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS WHICH IS TREATED WITH LINEZOLID plus RIFAMPIN COMBINATION

Basit Öğe Kaydı
dc.contributor.authorSipahi, Oguz Resat
dc.contributor.authorCagiran, Inanc
dc.contributor.authorYurtseven, Taskin
dc.contributor.authorTasbakan, Meltem Isikgoz
dc.contributor.authorArda, Bilgin
dc.contributor.authorTunger, Alper
dc.contributor.authorUlusoy, Sercan
dc.date.accessioned2019-10-27T21:14:44Z
dc.date.available2019-10-27T21:14:44Z
dc.date.issued2010
dc.departmentEge Üniversitesien_US
dc.description.abstractMethicillin-resistant Staphylococcus aureus (MRSA) is a rare cause of cerebral abscesses, however it is a relatively more common etiologic agent in post-neurosurgical abscesses and the main antibacterial therapy option is vancomycin. In this report, a case of brain abscess due to MRSA which did not respond neither to moxifloxacin + vancomycin nor vancomycin + rifampin combination therapies, and merely treated by linezolid + rifampin combination, has been presented. Fifty-one years old female patient who was operated 40 days ago for subarachnoid bleeding and aneurysm in middle cerebral artery bifurcation, was hospitalized due to purulent leakage from the operation area. She did not have fever and her physical examination, including the neurologic system, was normal. Computerized tomography revealed an approximately 1 cm lesion compatible with subdural empyema and cerebral abscess in the right frontoparietal area in supratentorial sections. The patient was operated for wound revision and moxifloxacin was initiated. Since the operation materials revealed MRSA growth, vancomycin (4 x 500 mg, IV) was added to the treatment. The isolate was identified by conventional methods, and antibiotic susceptibility test performed by disk diffusion method showed that it was susceptible to levofloxacin, linezolid, rifampin, vancomycin and teicoplanin. Since no clinical response was obtained in two weeks, moxifloxacin was switched to rifampin (300 mg 1 x 2). On the 10(th) day of vancomycin + rifampin therapy, radiological findings showed development of cerebritis and therefore vancomycin was changed with linezolid (2 x 600 mg, IV). The control CT of the patient revealed regression of the brain lesion and linezolid + rifampin treatment continued for six weeks. The patient did not develop any hematological, liver or renal toxicity during the therapy and the radiological findings regressed. No relapse were detected in the one year follow-up period. This case suggested that linezolid might be a treatment alternative in the therapy of vancomycin-refractory MRSA brain abscess.en_US
dc.identifier.endpage655en_US
dc.identifier.issn0374-9096
dc.identifier.issue4en_US
dc.identifier.pmid21063978en_US
dc.identifier.startpage651en_US
dc.identifier.urihttps://hdl.handle.net/11454/43432
dc.identifier.volume44en_US
dc.identifier.wosWOS:000284385400014en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isotren_US
dc.publisherAnkara Microbiology Socen_US
dc.relation.ispartofMikrobiyoloji Bultenien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBrain abscessen_US
dc.subjectmethicillin-resistant Staphylococcus aureusen_US
dc.subjectMRSAen_US
dc.subjectlinezoliden_US
dc.titleA CASE OF CEREBRAL ABSCESS DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS WHICH IS TREATED WITH LINEZOLID plus RIFAMPIN COMBINATIONen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu